-transparent.png){kind=logo}
Approximately five percent of pediatric acute lymphoblastic leukemias (ALL) contain a translocation (9;22)(q34;q11) which results in rearrangement of the bcr and abl genes. At a median follow-up of 5 years, we assessed the prognostic implications of translocation (9;22) in 434 children receiving intensive treatment for ALL. Four-year event-free and overall survivals were only 0% and 20%, respectively, in 15 children with translocation (9;22), but were 81% and 89%, respectively, in 419 children lacking translocation (9;22) (P < 0.001). Based on these findings, we recommend very intensive treatment approaches for all children with translocation (9;22)-positive ALL.
Related Publications
J A Fletcher, and
N Tu, and
R Tantravahi, and
S E Sallan
February 1991,
Blood,
J A Fletcher, and
N Tu, and
R Tantravahi, and
S E Sallan
September 2008,
American journal of hematology,
J A Fletcher, and
N Tu, and
R Tantravahi, and
S E Sallan
January 2018,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
J A Fletcher, and
N Tu, and
R Tantravahi, and
S E Sallan
January 1988,
Annales de genetique,
J A Fletcher, and
N Tu, and
R Tantravahi, and
S E Sallan
August 2006,
Leukemia research,
J A Fletcher, and
N Tu, and
R Tantravahi, and
S E Sallan
May 2009,
Future oncology (London, England),
J A Fletcher, and
N Tu, and
R Tantravahi, and
S E Sallan
April 2021,
International journal of laboratory hematology,
J A Fletcher, and
N Tu, and
R Tantravahi, and
S E Sallan
July 2015,
Pediatric annals,
J A Fletcher, and
N Tu, and
R Tantravahi, and
S E Sallan
May 1983,
British medical journal (Clinical research ed.),
J A Fletcher, and
N Tu, and
R Tantravahi, and
S E Sallan
January 2014,
Leukemia & lymphoma,
